Bryce Point Capital LLC Invests $790,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Bryce Point Capital LLC has invested $790,000 in Krystal Biotech, acquiring 4,286 shares, as disclosed in their 13F filing with the SEC.
• Analysts have varied target prices for Krystal Biotech, with a consensus price target of $211.33 and a general rating of "Buy"; notable upgrades include Citigroup's raise to $176.00.
• Insider trading activity is evident, with Suma Krishnan selling 1,389 shares for over $208,000 while insiders sold a total of 49,800 shares in the last three months.

Bryce Point Capital LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,286 shares of the company's stock, valued at approximately $790,000.

Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in Krystal Biotech in the fourth quarter valued at $34,391,000. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after acquiring an additional 141,400 shares in the last quarter. GAMMA Investing LLC raised its holdings in Krystal Biotech by 50,249.4% in the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after acquiring an additional 121,101 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $15,989,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after purchasing an additional 71,200 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity

In related news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded up $0.58 on Thursday, hitting $153.80. 224,686 shares of the stock were exchanged, compared to its average volume of 316,747. The stock has a market capitalization of $4.44 billion, a price-to-earnings ratio of 36.97 and a beta of 0.67. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $212.06. The company's 50-day moving average price is $139.62 and its 200 day moving average price is $155.63.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. Citigroup restated a "neutral" rating and set a $176.00 price objective (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Guggenheim cut their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Friday, July 25th. Finally, Bank of America reduced their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $211.33.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).